Pfizer Limited has disclosed the resignation of Amit Agarwal, who serves as Executive Director – Finance & Chief Financial Officer. The departure is effective October 8, 2026, at close of business. Agarwal stated he is leaving to pursue a professional opportunity outside the company.

The resignation was communicated to the Bombay Stock Exchange and the National Stock Exchange of India Ltd on July 27, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also complies with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Upon his exit, Agarwal will cease to hold his position on the Board of Directors. He will also step down from all Board committees where he currently serves as a member. These include the Corporate Social Responsibility Committee, the Risk Management Committee, and the Board Administrative & Share Transfer Committee.

Resignation Details

The following table outlines the key details of the leadership change as per the filing:

In his resignation letter addressed to the Board of Directors, Agarwal expressed gratitude for the trust and support received during his tenure. Prajeet Nair, Director – Corporate Services & Company Secretary, signed the intimation letter sent to the stock exchanges.

Bluesight and Pfizer Global Hospital & Biosimilars have partnered to integrate SmartDose RFID-enabled medications with the KitCheck inventory management platform. This collaboration enables hospitals using KitCheck to procure SmartDose medications that are already tagged, encoded, and pre-associated at the point of manufacture. By moving the tagging process upstream, the partnership aims to reduce manual tagging labor for pharmacists and pharmacy technicians while improving inventory management efficiency and patient safety.

An estimated one-third of U.S. hospitals currently use RFID technology to enhance inventory management, strengthen regulatory compliance, and reduce medication waste. The initiative seeks to advance a standardized, interoperable approach that preserves the efficiency, safety, and visibility benefits of RFID. Bluesight’s engineers collaborated with Pfizer to ensure SmartDose adheres to industry best practices, including GS1 global data standards and ARC Spec S performance benchmarks.

Technical Specifications and Quality Assurance

Unlike hospital-based tagging programs, SmartDose applies RFID labels during manufacturing using proven GS1 encoding strategies and rigorous quality assurance processes. Each vial undergoes individual, automated readback verification before release to confirm the tag is readable and correctly encoded. These consistent manufacturing controls are designed to deliver a more reliable and accurate product while reducing the complexity of hospital-managed tagging programs.

Executive Commentary

“At Pfizer, we looked at the workflow hospitals were performing and asked a simple question: Why should pharmacists and pharmacy technicians be doing work that can be completed at the point of manufacture?” said Erin Pezant, Global Business Excellence Lead at Pfizer Global Hospital & Biosimilars. “SmartDose was designed to remove unnecessary manual steps from the pharmacy by delivering medications that arrive already tagged and associated.”

Kevin MacDonald, CEO and co-founder of Bluesight, emphasized the collaborative nature of the supply chain. “For more than a decade, we've believed RFID works best when every part of the supply chain plays a role. Pfizer shares that vision, and this collaboration demonstrates what's possible when manufacturing and hospital workflow expertise come together.”

Pfizer SmartDose medications are projected to be available for purchase in the second half of 2026.